Monday’s listening session with FDA staff brought a substantive discussion of APC’s proposed...
APC, NCPA urge HHS to clarify peptide policy
APC and NCPA submitted joint comments November 13 supporting HHS’s interim peptide enforcement discretion policy while urging clarification and additional safeguards to make it workable for pharmacies and credible to state regulators.
As we wrote:
“The critical principle is straightforward: A manufacturer’s unsupported assertion of compliance should not be the only checkpoint before peptide API covered by the HHS enforcement discretion policy enters a pharmacy.”
And with several state boards already considering how to respond to the policy, we emphasized:
“Timely and accurate communication may reduce avoidable differences in interpretation, even where states ultimately exercise their own authority differently.”
We also urged HHS and FDA to publish a practical FAQ addressing questions pharmacies and state regulators need answered.
The comment period has closed. We'll keep you informed as HHS considers next steps.